Skip to main content
SpringerLink
Log in

Lupus Nephritis

Treatment Issues

  • Disease Management
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Effective treatment of lupus nephritis requires an understanding of disease pathogenesis, risk stratification by World Health Organization (WHO) classification and therapeutic options.

Mesangial lupus nephropathy is generally associated with an excellent prognosis, whereas proliferative lupus nephropathy, especially the diffuse variant, is often characterised by hypertension, red blood cell casts and significant deterioration of renal function. Nephrotic syndrome in the absence of hypertension, active urinary sediment or significant hypocomplementaemia suggests the membranous variant of lupus nephropathy. Membranous nephropathy generally confers a good prognosis. However, persistent nephrotic range proteinuria may be accompanied by loss of renal function and end stage renal disease.

Glucocorticoids, usually prednisone or methylprednisolone, remain the most effective, rapidly acting immunomodulatory therapy for both the initial episode or recurrence of active renal disease. A role for cyclophosphamide in the treatment of lupus nephritis has been established in prospective, randomised trials. The benefits of intravenous cyclophosphamide were seen in groups of patients failing prednisone, establishing cyclophosphamide as salvage or rescue therapy for patients unresponsive to glucocorticoids. Additional therapeutic strategies include azathioprine, cyclosporin, and plasmapheresis.

Ancillary management can consist of hypertension control, use of angiotensin-converting enzyme inhibitors, dietary restriction of salt and protein, and lipid lowering drugs.

Current treatment of lupus nephritis is associated with preservation of renal function in the vast majority of patients; however, novel agents that are more effective and less toxic are required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wallace DJ. The clinical presentation of systemic lupus erythematosus. In: Wallace DJ, BH Hahn, editors. Dubois’ lupus erythematosus. Baltimore: Williams & Wilkins, 1996: 627

    Google Scholar 

  2. Skovron ML, Petri M. Frequency of renal manifestations in the Johns Hopkins SLE Cohort [abstract]. Arthritis Rheum 1997; 40(9): S220

    Google Scholar 

  3. Lee HS, Spargo BH. A renal biopsy study of lupus nephropathy in the United States and Korea. Am J Kidney Dis 1985; 5: 242–50

    PubMed  CAS  Google Scholar 

  4. Dooley MA, Hogan S, Jennette C, et al. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997; 51: 1188–95

    Article  PubMed  CAS  Google Scholar 

  5. Appel GB. Cyclophosphamide therapy of severe lupus nephritis. Am J Kidney Dis 1997; 30: 872–6

    Article  PubMed  CAS  Google Scholar 

  6. Pistiner M, Wallace DJ, Nessim S, et al. Lupus erythematosus in the 1980’s: a survey of 570 patients. Semin Rheum Dis 1991; 21: 55–64

    Article  CAS  Google Scholar 

  7. Freedman BI, Spray BJ, Heise ER, et al. A race-controlled human leukocyte antigen frequency analysis in lupus nephritis. Am J Kidney Dis 1993; 21: 378–82

    PubMed  CAS  Google Scholar 

  8. Klippel JH. Predicting who will get lupus nephritis. J Clin Rheumatol 1995; 1: 257–9

    Article  PubMed  CAS  Google Scholar 

  9. Salmon JE, Millard SS, Schachter LA, et al. FcgRIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996; 97: 1348–54

    Article  PubMed  CAS  Google Scholar 

  10. Duits J, Bootsma H, Derksen RH, et al. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal diseases in systemic lupus erythematosus patients. Arthritis Rheum 1995; 38: 1832–6

    Article  PubMed  CAS  Google Scholar 

  11. Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus: interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996; 39: 9–22

    Article  PubMed  CAS  Google Scholar 

  12. Frampton G, Hicks J, Cameron JS. Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int 1991; 39: 1225–31

    Article  PubMed  CAS  Google Scholar 

  13. Schur PH, Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968; 278: 533–8

    Article  PubMed  CAS  Google Scholar 

  14. ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis Rheum 1990; 33: 634–43

    Article  PubMed  Google Scholar 

  15. Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus: increased prednisone reduced minor relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595–9

    Article  PubMed  CAS  Google Scholar 

  16. Koscec M, Koren E, Wolfson-Reichlin M, et al. Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J Immunol 1997; 159: 2033–41

    PubMed  CAS  Google Scholar 

  17. Martin AL, Reichlin M. Fluctuations of antibody to ribosomal P proteins correlate with appearance and remission of nephritis in SLE. Lupus 1998; 5: 22–9

    Google Scholar 

  18. Hulsey M, Goldstein R, Sculley L, et al. Anti-ribosomal P antibodies in systemic lupus erythematosus: a case-control study correlating hepatic and renal disease. Clin Immunol Immunopath 1995; 74: 252–6

    Article  CAS  Google Scholar 

  19. Gunnarsson I, Ronnelid J, Huang YH, et al. Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus. Br J Rheumatol 1997; 36: 32–7

    Article  PubMed  CAS  Google Scholar 

  20. Mannik M, Wener MH. Deposition of antibodies to the collagen-like region of C1q in renal glomeruli or patients with proliferative lupus glomerulonephritis. Arthritis Rheum 1997; 40: 1504–11

    Article  PubMed  CAS  Google Scholar 

  21. Dubois EL. Lupus erythematosus. Areview of the current status of discoid and systemic lupus erythematosus and their variants. 2nd ed. Los Angeles: USC Press, 1976

    Google Scholar 

  22. Appel GB, Cohen DJ, Pirani CL, et al. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987; 83: 877–85

    Article  PubMed  CAS  Google Scholar 

  23. Austin HA III, Muenz LR, Joyce KM, et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689–95

    Article  PubMed  Google Scholar 

  24. Balow JE, Austin III HA, Muenz LR. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984; 311: 491–5

    Article  PubMed  CAS  Google Scholar 

  25. Schwartz MM, Lan SP, Bernstein J, et al. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 1993; 21: 374–7

    PubMed  CAS  Google Scholar 

  26. Wernick RM, Smith DL, Houghton DC, et al. Reliability of histologic scoring for lupus nephritis: a community-based evaluation. Ann Intern Med 1993; 119: 805–11

    PubMed  CAS  Google Scholar 

  27. Austin HA III, Boumpas DT, Vaughan EM, et al. Predicting renal outcomes in severe lupus nephritis. contributions of clinical and histologic data. Kidney Int 1994; 45: 544–50

    Article  PubMed  Google Scholar 

  28. Tateno S, Kobayashi Y, Shigematsu H, et al. Study of lupus nephritis: its classification and the significance of subendothelial deposits. J Medicine, New Series LII 1983; 207: 311–31

    Google Scholar 

  29. Font J, Torras A, Cevera R, et al. Silent renal disease in systemic lupus erythematosus. Clin Nephrol 1987; 27: 283–8

    PubMed  CAS  Google Scholar 

  30. Kimberly RP, Lockshin MD, Sherman RL, et al. High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am J Med 1981; 70: 817–25

    Article  PubMed  CAS  Google Scholar 

  31. Gourley MF, Austin Ha, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 1997; 125: 549–57

    Google Scholar 

  32. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614–9

    Article  PubMed  Google Scholar 

  33. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone alone. Arthritis Rheum 1991; 34: 945–50

    Article  PubMed  CAS  Google Scholar 

  34. Boumpas DT, Austin III HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741–5

    Article  PubMed  CAS  Google Scholar 

  35. McCune WJ, Golbus J, Zeldes W, et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318: 1423–51

    Article  PubMed  CAS  Google Scholar 

  36. Belmont HM, Storch M, Buyon J, et al. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 1995; 4: 104–8

    Article  PubMed  CAS  Google Scholar 

  37. Du LTH, Piette J-C, Faucher C, et al. Efficacy and limits of intravenous cyclophosphamide (IVCP) in systemic lupus erythematosus (SLE). An open study in 45 cases [abstract]. Arthritis Rheum 1991; 34: S58

    Google Scholar 

  38. Lehman TJA, Sherry DD, Wagner-Weiner L, et al. Intermittent intravenous cyclophosphamide for lupus nephritis. J Pediatr 1989; 114: 1055–60

    Article  PubMed  CAS  Google Scholar 

  39. Wagner-Weiner L, Emery H, Spencer C, et al. Intravenous pulse cyclophosphamide therapy (IVCY) for childhood lupus nephritis: variable renal outcomes at 3 to 7 year follow-up [abstract]. Arthritis Rheum 1991; 34: S58

    Google Scholar 

  40. Martin-Suarez I, D’Cruz D, Mansoor M, et al. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997; 56: 481–7

    Article  PubMed  CAS  Google Scholar 

  41. Boumpas DT, Austin III HA, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366–9

    PubMed  CAS  Google Scholar 

  42. Masala A, Faedda R, Alagna S, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Int Med 1998; 126: 292–5

    Google Scholar 

  43. Petri M, Buyon J, Kim M, for the SELENA Group. Differences in pre vs post-menopausal SLE: the SELENA trial. Arthritis Rheum 1998; 41: S67

    Google Scholar 

  44. Felson DT, Anderson J. Evidence for the superiority of immunosuppresive drugs and prednisone over prednisone alone in lupus nephritis. results of a pooled analysis. N Engl J Med 1984; 311: 1528–33

    Article  PubMed  CAS  Google Scholar 

  45. Bansal VK, Beto JA. Treatment of lupus nephritis. A meta-analysis of clinical trials. Am J Kidney Dis 1997; 29(2): 193–9

    Article  PubMed  CAS  Google Scholar 

  46. Caccavo D, Lagana B, Mitterhofer AP, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 1997; 40(1): 27–35

    Article  PubMed  CAS  Google Scholar 

  47. Manger K, Kalden JR, Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1997; 35: 669–75

    Article  Google Scholar 

  48. Radhakrishnan J, Kunis CL, D’Agati V, et al. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994; 42: 147–54

    PubMed  CAS  Google Scholar 

  49. Lewis EJ, Hunsicker LG, Lan S-P, et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992; 326: 1373–9

    Article  PubMed  CAS  Google Scholar 

  50. Heyneman CA, Gudger CA, Beckwith JV. Intravenous immune globulin for inducing remissions in systemic lupus erythematosus. Ann Pharmacother 1997; 31: 242–4

    PubMed  CAS  Google Scholar 

  51. Schroeder JO, Zeuner RA, Euler HH, et al. High dose intravenous immunoglobulins in systemic lupus erythematosus. clinical and serological results of a pilot study. J Rheumatol 1996; 23: 71–5

    PubMed  CAS  Google Scholar 

  52. Francioni C, Galeazzi M, Fioravanti A, et al. Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12: 163–8

    PubMed  CAS  Google Scholar 

  53. Dooley MA, Nachman PH, Satterly KK, et al. Mycophenylate mofetil therapy in resistant or relapsing diffuse proliferative lupus nephritis (SLE-DPGN) following cyclophosphamide (CyP) therapy [abstract]. Arthritis Rheum 1997; 40(9) Suppl.: S58

    Google Scholar 

  54. Corna D, Moriga M, Facchinetti D, et al. Mycophenolate mofetil limits renal damage in murine lupus autoimmune disease. Kidney Int 1997; 51: 1583–9

    Article  PubMed  CAS  Google Scholar 

  55. Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular diseases. Am J Kidney Dis 1998; 31: 213–7

    Article  PubMed  CAS  Google Scholar 

  56. Pashinian N, Wallace D. Klineneberg JR. Mycophenolate mofetil for systemic lupus erythematosus. Arthritis Rheum 1998;41: S110

    Article  Google Scholar 

  57. Davis JC, Jr, Austin H III, Boumpas D, et al. A pilot study of 2-chloro-2-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum 1998; 41: 335–43

    Article  PubMed  CAS  Google Scholar 

  58. Euler HH, Gutschmidt HT, Schmuecking M, et al. Induction of remission in severe SLE after plasma exchange synchronized with subsequent pulse cyclophosphamide. Prog Clin Biol Res 1990; 337: 319–20

    PubMed  CAS  Google Scholar 

  59. Wallace D, Goldfinger D, Pepkowitz S. A prospective, controlled trial of pulse synchronization cyclophosphamide (CTX)/apheresis for proliferative lupus nephritis [abstract]. Arthritis Rheum 1997; 40(9): S58

    Google Scholar 

  60. Schroeder JO, Schwab U, Zeuner R, et al. Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. Arthritis Rheum 1997; 40: S325

    Google Scholar 

  61. Ahsan N, Wiegand LA, Abendroth CS, et al. Acute renal failure following immunoglobulin therapy. Am J Nephrol 1996; 16: 532–6

    Article  PubMed  CAS  Google Scholar 

  62. Silvestris F, D’Amore O, Cafforio P, et al. Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG. Clin Exp Imunol 1996; 104: 91–7

    Google Scholar 

  63. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993–7

    Article  PubMed  CAS  Google Scholar 

  64. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 335: 596–7

    Article  Google Scholar 

  65. Mojcik CF, Klippel JH. End-stage renal disease and systemic lupus erythematosus. Am J Med 1996; 101: 100–7

    Article  PubMed  CAS  Google Scholar 

  66. Coutts SM, Plunkett ML, Iverson GM, et al. Pharmacological intervention in antibody mediated disease. Lupus 1996; 5: 158–9

    Article  PubMed  CAS  Google Scholar 

  67. Weisman MH, Bluestein HG, Berner CM, et al. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997; 24: 314–8

    PubMed  CAS  Google Scholar 

  68. Biancone L, Andres G, Ahn H, et al. Inhibition of the CD40-CD40 ligand pathway prevents murine membraneous glomerulonephritis. Kidney Int 1995; 48: 458–68

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital for Joint Diseases, New York University School of Medicine, 301 East 17th Street, New York, New York, 10003, USA

    H. Michael Belmont (Assistant Clinical Professor of Medicine, Director Lupus Clinics Hospital for Joint Diseases and Bellevue Hospital Center)

Authors
  1. H. Michael Belmont
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Michael Belmont.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Belmont, H.M. Lupus Nephritis. BioDrugs 11, 7–19 (1999). https://doi.org/10.2165/00063030-199911010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199911010-00002

Keywords

Search

Navigation